- Home
- PDSB vs MAIA Comparison
PDSB vs MAIA Comparison
Compare PDSB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- MAIA
- Stock Information
- Founded
- PDSB 2005
- MAIA 2018
- Country
- PDSB United States
- MAIA United States
- Employees
- PDSB N/A
- MAIA N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- MAIA Health Care
- Exchange
- PDSB Nasdaq
- MAIA Nasdaq
- Market Cap
- PDSB 43.1M
- MAIA 46.7M
- IPO Year
- PDSB N/A
- MAIA 2022
- Fundamental
- Price
- PDSB $1.28
- MAIA $1.98
- Analyst Decision
- PDSB Strong Buy
- MAIA
- Analyst Count
- PDSB 3
- MAIA 0
- Target Price
- PDSB $10.00
- MAIA N/A
- AVG Volume (30 Days)
- PDSB 279.1K
- MAIA 156.7K
- Earning Date
- PDSB 05-14-2025
- MAIA 05-13-2025
- Dividend Yield
- PDSB N/A
- MAIA N/A
- EPS Growth
- PDSB N/A
- MAIA N/A
- EPS
- PDSB N/A
- MAIA N/A
- Revenue
- PDSB N/A
- MAIA N/A
- Revenue This Year
- PDSB N/A
- MAIA N/A
- Revenue Next Year
- PDSB N/A
- MAIA N/A
- P/E Ratio
- PDSB N/A
- MAIA N/A
- Revenue Growth
- PDSB N/A
- MAIA N/A
- 52 Week Low
- PDSB $0.85
- MAIA $1.40
- 52 Week High
- PDSB $4.42
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- PDSB 59.26
- MAIA 65.72
- Support Level
- PDSB $1.00
- MAIA $1.51
- Resistance Level
- PDSB $1.17
- MAIA $2.25
- Average True Range (ATR)
- PDSB 0.10
- MAIA 0.14
- MACD
- PDSB 0.04
- MAIA 0.07
- Stochastic Oscillator
- PDSB 91.84
- MAIA 70.15
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.